May 7th 2024
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Laparoscopy/robotics studies explore the limits of minimally invasive surgery
April 17th 2014Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
Urology Product Preview April 2014
April 16th 2014Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.
‘Obesity paradox’ appears to fit for men with renal cell carcinoma
April 10th 2014A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.
Gene set breaks high-grade bladder cancer into two subtypes
April 10th 2014Researchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes-basal-like and luminal-each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.
AUA Exhibit Hall Highlights: Orlando 2014
April 2nd 2014This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
Sequential therapies for metastatic renal cell carcinoma yield similar results
March 21st 2014The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
Robotic nephrectomy on the rise, but why?
February 24th 2014The advantages that robotic technologies bring to prostate procedures, partial nephrectomies, and other surgeries that can involve complex reconstruction are not readily apparent in simple extirpative surgeries such as radical nephrectomy. This raises two questions: Are robots being used in radical nephrectomies and if so, why?
Breast cancer drug may play role in bladder cancer
January 27th 2014Mayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Robotic partial nephrectomy: Renal function loss low in CKD patients
January 20th 2014Patients with chronic kidney disease who undergo robot-assisted partial nephrectomy for kidney cancer have minimal loss of renal function-a smaller amount even than patients with normal kidney function, according to researchers at Henry Ford Hospital in Detroit, who say their study is the largest of its kind.
New Urology Products and Services November 2013
October 29th 2013The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.
Agent shows promise in slowing papillary kidney cancer
October 21st 2013The first phase II study to investigate the use of the targeted therapy everolimus (Afinitor) for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease.
Study may signify shift in RCC standard of care
August 23rd 2013The tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.